Eisai Co Ltd (4523):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Eisai Co Ltd (4523) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7165
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eisai Co Ltd (Eisai) is a pharmaceutical company that undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs, prescription medicines and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex (proton pump inhibitor); Aricept, an anti-Alzheimer’s agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.

Eisai Co Ltd (4523) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eisai Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eisai Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Eisai Co Ltd, Medical Equipment, Deal Details 11
Partnerships 11
Fujirebio Diagnostics Enters into Licensing Agreement with Morphotek for Farletuzumab 11
Biocare Medical Enters into Licensing Agreement with Morphotek 12
Eisai Enters into Co-Development Agreement with MAMORIO 13
Cancer Genetics Partners with H3 Biomedicine 14
Eisai Enters into Agreement with Sysmex 15
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 16
Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 17
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 18
Acquisition 19
Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 19
Robert Bosch Completes Acquisiton Of Eisai Machinery 20
Eisai Co Ltd – Key Competitors 22
Eisai Co Ltd – Key Employees 23
Eisai Co Ltd – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Joint Venture 29
Recent Developments 30
Strategy And Business Planning 30
Jan 11, 2018: Eisai Completes Construction Of Oral Solid Dose Production Facility At New Suzhou Plant In China 30
Corporate Communications 31
Oct 10, 2018: Eisai to support earthquake relief efforts in sulawesi, indonesia 31
Aug 27, 2018: Stephen Davies appointed Vice President, Eisai strategic information systems at Eisai 32
Jul 18, 2018: Eisai supports relief efforts for flooding in western Japan 33
Jul 04, 2018: Eisai Listed For 17th Consecutive Year In FTSE4GOOD Index Series, An Index For Socially Responsible Investment 34
Jun 11, 2018: Eisai Names Lihua Yu As President & Chief Data Sciences Officer Of H3 Biomedicine 35
Feb 20, 2018: EISAI Certified In 2018 As Outstanding Health And Productivity Management Organization (WHITE 500) 36
Nov 20, 2017: Eisai Receives IT Business Award For Medication Administration Support Device e-OKUSURI-SAN Equipped With Functions To Support Looking After Patients 37
Sep 25, 2017: Eisai to Contribute to Central Mexican Earthquake Relief Efforts 38
May 10, 2017: Eisai: Proposed Changes in Representative Officers 39
Government and Public Interest 40
Jun 28, 2017: Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment 40
Product News 41
Jan 12, 2017: Eisai To Launch Medication Administration Support Device e-OKUSURI-SAN 41
Other Significant Developments 42
Oct 31, 2017: GHIT Fund Accelerates Promising Efforts to Find New Treatments, Vaccines and Diagnostics for Malaria, Tuberculosis, Leishmaniasis and Mycetoma 42
Sep 12, 2017: Eisai and MAMORIO to Jointly Launch “Me-MeMAMORIO” Tracking Tool to Support People With Dementia and Seniors Going Out 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Eisai Co Ltd, Medical Equipment, Key Facts, 2018 2
Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eisai Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eisai Co Ltd, Deals By Market, 2012 to YTD 2018 9
Eisai Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Fujirebio Diagnostics Enters into Licensing Agreement with Morphotek for Farletuzumab 11
Biocare Medical Enters into Licensing Agreement with Morphotek 12
Eisai Enters into Co-Development Agreement with MAMORIO 13
Cancer Genetics Partners with H3 Biomedicine 14
Eisai Enters into Agreement with Sysmex 15
H3 Biomedicine And BGI Enter Into Agreement To Develop And Share Cancer Genomic Sequencing Data 16
Epizyme, Eisai And Roche Enter Into Co-Development Agreement For Companion Diagnostic Test 17
Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 18
Sekisui Chemical to Acquire Eidia from Eisai for USD182 Million 19
Robert Bosch Completes Acquisiton Of Eisai Machinery 20
Eisai Co Ltd, Key Competitors 22
Eisai Co Ltd, Key Employees 23
Eisai Co Ltd, Subsidiaries 26
Eisai Co Ltd, Joint Venture 29

List of Figures
Eisai Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Eisai Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Eisai Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Eisai Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Eisai Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Eisai Co Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Eisai Co Ltd (4523):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • J. Front Retailing Co., Ltd.:戦略・SWOT・企業財務分析
    J. Front Retailing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary J. Front Retailing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Development Bank of Southern Africa:企業の戦略的SWOT分析
    Development Bank of Southern Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • NeoPharm Co Ltd:企業の戦略・SWOT・財務分析
    NeoPharm Co Ltd - Strategy, SWOT and Corporate Finance Report Summary NeoPharm Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sirius XM Holdings Inc.:企業の戦略・SWOT・財務情報
    Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ABO-Group NV (ABO):企業の財務・戦略的SWOT分析
    Summary ABO-Group NV (ABO-Group), formerly Thenergo NV/SA, is a renewable energy service provider. It offers energy services, soil, environment, geotechnics and waste management services. The company’s services include consulting, training and monitoring services. Its soil services comprise groundwa …
  • Lincoln Electric System:発電所・企業SWOT分析
    Lincoln Electric System - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Fresenius Medical Care AG & Co KGaA (FMS):医療機器:M&Aディール及び事業提携情報
    Summary Fresenius Medical Care AG & Co KGaA (Fresenius Medical), a subsidiary of Fresenius SE & Co KGaA, is an integrated dialysis company. It is one of the largest kidney dialysis companies in the world. It provides dialysis care services and products to individuals with chronic kidney failure. It …
  • Cypralis Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Cypralis Ltd (Cypralis), formerly Selcia Pharma Ltd is a drug developer that provides discovery and development of therapeutics targeting peptidyl-prolyl isomerases. The company spans its expertise in the development of medicines for degenerative diseases such as acute tissue injury, liver d …
  • Caspian Sunrise Plc (CASP):石油・ガス:M&Aディール及び事業提携情報
    Summary Caspian Sunrise Plc (Caspian), formerly Roxi Petroleum plc, is an oil and gas exploration and development company. The company acquires, explores and develops crude oil. It holds interests in the exploration and production of BNG contract area in the Pre-Caspian basin and the Mangyshlak basi …
  • Aeris Resources Limited:企業の戦略・SWOT・財務情報
    Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ITL Health Group (ITD):企業の財務・戦略的SWOT分析
    ITL Health Group (ITD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Syntimmune Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Syntimmune Inc (Syntimmune) is a clinical-stage biotechnology company that focuses to develop Fc receptor (FcRn) based antibody therapeutics for the treatment of autoimmune diseases. Its lead pipeline products includes SYNT001, an investigational humanized IgG4 monoclonal antibody that inhib …
  • Capital Properties Inc (CPTP):企業の財務・戦略的SWOT分析
    Summary Capital Properties Inc (Capital Properties) is a real estate company that acquires, operates, develops, and manages real estate properties. The company's services include real estate management, investment, and development and petroleum storage operations with lease interests in downtown pro …
  • ULURU Inc (ULUR)-医療機器分野:企業M&A・提携分析
    Summary ULURU Inc (ULURU) is a developer and commercializer of wound care and muco-adhesive film products. The company’s products include Altrazeal and OraDisc. Its Altrazeal is a transforming powder dressing with Nanoflex technology for the management of exuding wounds. ULURU’s OraDisc is a polymer …
  • Knights of Columbus:企業の戦略的SWOT分析
    Knights of Columbus - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Vornado Realty Trust:企業の戦略・SWOT・財務情報
    Vornado Realty Trust - Strategy, SWOT and Corporate Finance Report Summary Vornado Realty Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • NuGEN Technologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary NuGEN Technologies Inc (NuGEN) is a provider of biological science reagents. The company provides DNA and RNA sample preparation products for use in research and diagnostic applications. Its products include Next-Gen Sequencing applications, which include RNA-Seq, targeted resequencing of DN …
  • APA Group:企業のM&A・事業提携・投資動向
    APA Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's APA Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Trovagene Inc (TROV):医療機器:M&Aディール及び事業提携情報
    Summary Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1 (PLK1) inhibitor that helps treat solid tumor cancers and multiple hematologic malignancie …
  • CBS Corporation:企業の戦略・SWOT・財務情報
    CBS Corporation - Strategy, SWOT and Corporate Finance Report Summary CBS Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆